Payment overview · 2025
General Payments
$749.75
32 reported records · 12 companies
Healthcare provider profile · identity verified
Ahsan Usman, MD
Allopathic & Osteopathic Physicians|Hospitalist · BELLEVILLE, IL · NPI 1215016571
Verified facts
What the public records show
CMS Open Payments records show Ahsan Usman, MD received $749.75 in general payments during 2025 across 32 reported records.
Novo Nordisk Inc accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic, Rexulti.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOKELMA as an associated drug or biological on 6897 records involving 4326 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Lokelma by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 297 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $143.55 | 19.1% | 11 | 2025 |
| Vantive US Healthcare LLC | Unresolved — no canonical attribution shown | $117.17 | 15.6% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $90.28 | 12.0% | 4 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $89.75 | 12.0% | 4 | 2025 |
| Alpha Cognition USA, Inc. | Unresolved — no canonical attribution shown | $59.82 | 8.0% | 1 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $47.06 | 6.3% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.82 | 6.2% | 2 | 2025 |
| Fresenius USA Marketing, Inc. | Unresolved — no canonical attribution shown | $43.92 | 5.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $32.51 | 4.3% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.04 | 3.9% | 1 | 2025 |
| AKEBIA THERAPEUTICS INC | Unresolved — no canonical attribution shown | $26.08 | 3.5% | 1 | 2025 |
| Travere Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.75 | 3.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $749.75 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $143.55 | 11 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $125.77 | 6 | 2025 |
Source payment records
|
|||||
| Renal - PD Normalized: renal pd |
Device | Vantive US Healthcare LLC | $117.17 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $71.18 | 5 | 2025 |
Source payment records
|
|||||
| Zunveyl Normalized: zunveyl |
Drug | Alpha Cognition USA, Inc. | $59.82 | 1 | 2025 |
Source payment records
|
|||||
| JYNARQUE Normalized: jynarque |
Drug | Otsuka America Pharmaceutical, Inc. | $54.26 | 2 | 2025 |
Source payment records
|
|||||
| TERLIVAZ Normalized: terlivaz |
Drug | Mallinckrodt Hospital Products Inc. | $47.06 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.82 | 2 | 2025 |
Source payment records
|
|||||
| VELPHORO Normalized: velphoro |
Drug | Fresenius USA Marketing, Inc. | $43.92 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $32.51 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $29.04 | 1 | 2025 |
Source payment records
|
|||||
| Vafseo Normalized: vafseo |
Drug | AKEBIA THERAPEUTICS INC | $26.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 116 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 297 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 39 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
116 | 18 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LOKELMA open payments reported associated product |
CMS Open Payments — General Payments 6897 supporting records · 4326 recipient NPIs · example record 1206131624 |
Lokelma · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
297 | 32 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Furosemide | Furosemide | 1389 | 214 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1250 | 182 |
| Eliquis | Apixaban | 911 | 106 |
| Gabapentin | Gabapentin | 814 | 129 |
| Levothyroxine Sodium | Levothyroxine Sodium | 672 | 113 |
| Sertraline Hcl | Sertraline Hcl | 571 | 77 |
| Pantoprazole Sodium | Pantoprazole Sodium | 568 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 561 | 109 |
| Potassium Chloride | Potassium Chloride | 498 | 110 |
| Levetiracetam | Levetiracetam | 446 | 54 |
| Trazodone Hcl | Trazodone Hcl | 431 | 66 |
| Lisinopril | Lisinopril | 422 | 67 |
| Famotidine | Famotidine | 406 | 63 |
| Metformin Hcl | Metformin Hcl | 398 | 61 |
| Metoprolol Tartrate | Metoprolol Tartrate | 394 | 73 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 377 | 77 |
| Carvedilol | Carvedilol | 363 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 332 | 74 |
| Metoprolol Succinate | Metoprolol Succinate | 326 | 70 |
| Buspirone Hcl | Buspirone Hcl | 322 | 54 |
| Duloxetine Hcl | Duloxetine Hcl | 320 | 42 |
| Losartan Potassium | Losartan Potassium | 304 | 59 |
| Jardiance | Empagliflozin | 297 | 32 |
| Mirtazapine | Mirtazapine | 294 | 49 |
| Omeprazole | Omeprazole | 287 | 64 |
| Allopurinol | Allopurinol | 259 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 259 | 56 |
| Donepezil Hcl | Donepezil Hcl | 229 | 44 |
| Tizanidine Hcl | Tizanidine Hcl | 228 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 205 | 33 |
| Lorazepam | Lorazepam | 201 | 60 |
| Tramadol Hcl | Tramadol Hcl | 199 | 57 |
| Hydralazine Hcl | Hydralazine Hcl | 187 | 32 |
| Memantine Hcl | Memantine Hcl | 181 | 26 |
| Myrbetriq | Mirabegron | 177 | 16 |
| Xarelto | Rivaroxaban | 173 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 171 | 34 |
| Simvastatin | Simvastatin | 170 | 30 |
| Spironolactone | Spironolactone | 170 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 27 |
| Baclofen | Baclofen | 158 | 30 |
| Entresto | Sacubitril/Valsartan | 157 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 157 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 156 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 154 | 30 |
| Warfarin Sodium | Warfarin Sodium | 140 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 135 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 132 | 19 |
| Sucralfate | Sucralfate | 131 | 19 |
| Aripiprazole | Aripiprazole | 126 | 17 |
| Meloxicam | Meloxicam | 126 | 12 |
| Montelukast Sodium | Montelukast Sodium | 125 | 15 |
| Risperidone | Risperidone | 124 | 19 |
| Farxiga | Dapagliflozin Propanediol | 116 | 18 |
| Januvia | Sitagliptin Phosphate | 115 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 115 | 34 |
| Metolazone | Metolazone | 112 | 30 |
| Olanzapine | Olanzapine | 110 | 24 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 109 | 45 |
| Ondansetron Odt | Ondansetron | 109 | 59 |
| Divalproex Sodium | Divalproex Sodium | 108 | 20 |
| Finasteride | Finasteride | 105 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 105 | 14 |
| Atropine Sulfate | Atropine Sulfate | 102 | 11 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 99 | suppressed |
| Lacosamide | Lacosamide | 98 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 95 | 12 |
| Prednisone | Prednisone | 95 | 33 |
| Midodrine Hcl | Midodrine Hcl | 94 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 88 | 23 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 21 |
| Glipizide | Glipizide | 84 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 80 | 22 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 79 | 56 |
| Pregabalin | Pregabalin | 79 | 12 |
| Sevelamer Carbonate | Sevelamer Carbonate | 79 | 13 |
| Meclizine Hcl | Meclizine Hcl | 77 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 48 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 75 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 73 | 34 |
| Novolog Flexpen | Insulin Aspart | 72 | 16 |
| Lactulose | Lactulose | 71 | 20 |
| Albuterol Sulfate | Albuterol Sulfate | 69 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 69 | 42 |
| Metoclopramide Hcl | Metoclopramide Hcl | 69 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 65 | 26 |
| Methenamine Hippurate | Methenamine Hippurate | 65 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | 13 |
| Enoxaparin Sodium | Enoxaparin Sodium | 64 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 63 | 19 |
| Alprazolam | Alprazolam | 62 | 19 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 61 | 31 |
| Clonazepam | Clonazepam | 60 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 59 | suppressed |
| Methimazole | Methimazole | 59 | suppressed |
| Tradjenta | Linagliptin | 59 | suppressed |
| Cephalexin | Cephalexin | 58 | 43 |
| Nystatin | Nystatin | 58 | 41 |
| Atenolol | Atenolol | 57 | 11 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 13 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 53 | 19 |
| Alendronate Sodium | Alendronate Sodium | 52 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 52 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 51 | 29 |
| Haloperidol | Haloperidol | 50 | suppressed |
| Nifedipine Er | Nifedipine | 50 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 15 |
| Vascepa | Icosapent Ethyl | 49 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 48 | 22 |
| Azithromycin | Azithromycin | 47 | 33 |
| Budesonide | Budesonide | 47 | suppressed |
| Caplyta | Lumateperone Tosylate | 47 | suppressed |
| Trulicity | Dulaglutide | 47 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 46 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | suppressed |
| Glimepiride | Glimepiride | 46 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 45 | suppressed |
| Latanoprost | Latanoprost | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Fiasp | Insulin Aspart (Niacinamide) | 44 | 11 |
| Topiramate | Topiramate | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Bumetanide | Bumetanide | 42 | 11 |
| Chlorthalidone | Chlorthalidone | 42 | suppressed |
| Dexamethasone | Dexamethasone | 42 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 40 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 40 | 32 |
| Memantine Hcl Er | Memantine Hcl | 40 | suppressed |
| Torsemide | Torsemide | 40 | suppressed |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 39 | suppressed |
| Rexulti | Brexpiprazole | 39 | suppressed |
| Glucagon Emergency Kit | Glucagon | 38 | 14 |
| Santyl | Collagenase Clostridium Hist. | 38 | 22 |
| Mupirocin | Mupirocin | 37 | 16 |
| Divalproex Sodium Er | Divalproex Sodium | 36 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 24 |
| Nitroglycerin | Nitroglycerin | 35 | 29 |
| Ramelteon | Ramelteon | 35 | 12 |
| Zonisamide | Zonisamide | 35 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 34 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Calcium Acetate | Calcium Acetate | 34 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 31 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 29 | 29 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 29 | 25 |
| Calcitriol | Calcitriol | 28 | suppressed |
| Ertapenem | Ertapenem Sodium | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 21 |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Folic Acid | Folic Acid | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 26 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 26 | suppressed |
| Olanzapine Odt | Olanzapine | 26 | suppressed |
| Ranolazine Er | Ranolazine | 26 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 26 | suppressed |
| Cefdinir | Cefdinir | 25 | 20 |
| Diltiazem Hcl | Diltiazem Hcl | 25 | suppressed |
| Lansoprazole | Lansoprazole | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 18 |
| Levemir | Insulin Detemir | 24 | suppressed |
| Scopolamine | Scopolamine | 24 | suppressed |
| Levetiracetam Er | Levetiracetam | 23 | suppressed |
| Loperamide | Loperamide Hcl | 23 | 19 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Mirabegron Er | Mirabegron | 22 | 12 |
| Morphine Sulfate | Morphine Sulfate | 22 | 18 |
| Prazosin Hcl | Prazosin Hcl | 22 | suppressed |
| Xifaxan | Rifaximin | 22 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 21 | 11 |
| Metronidazole | Metronidazole | 21 | 13 |
| Timolol Maleate | Timolol Maleate | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 13 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 17 |
| Phenobarbital | Phenobarbital | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | 12 |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | suppressed |
| Fetzima | Levomilnacipran Hcl | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Ozempic | Semaglutide | 19 | suppressed |
| Valproic Acid | Valproic Acid | 19 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Enulose | Lactulose | 18 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 18 | suppressed |
| Klor-Con M20 | Potassium Chloride | 18 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 18 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 18 | suppressed |
| Nyamyc | Nystatin | 18 | 14 |
| Nystop | Nystatin | 18 | 13 |
| Amoxicillin | Amoxicillin | 17 | 15 |
| Benztropine Mesylate | Benztropine Mesylate | 17 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 17 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 17 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Meropenem | Meropenem | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 17 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 17 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Anastrozole | Anastrozole | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | 12 |
| Linzess | Linaclotide | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Methadone Hcl | Methadone Hcl | 15 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 15 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 15 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 15 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Dropsafe Pen Needle | Pen Needle, Diabetic, Safety | 13 | 11 |
| Letrozole | Letrozole | 13 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Acetazolamide Er | Acetazolamide | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Aptiom | Eslicarbazepine Acetate | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Linezolid | Linezolid | 12 | 11 |
| Riluzole | Riluzole | 12 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Meropenem-0.9% Nacl | Meropenem-0.9% Sodium Chloride | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $749.75 · 32 records | Novo Nordisk Inc | FARXIGA, JARDIANCE, JYNARQUE, Kerendia, Ozempic, REXULTI, Renal - PD, Rybelsus, TERLIVAZ, VELPHORO, Vafseo, Zunveyl | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error